MyD88
MyD88 was first described in 1990 as a gene upregulated during IL-6-induced myeloid differentiation. MyD88 was implicated in signaling downstream of IL-1R and mammalian TLRs. The C-terminal TIR (Toll IL-1R) domain mediates the interaction with other TIR domain-containing proteins (receptors or adaptors); the N-terminal death domain (DD) associates with the IRAK family members through homotypic DD interactions. Consistent with these roles, overexpression of the DD of MyD88 leads to spontaneous activation of NFκB and c-Jun N-terminal kinase (JNK), whereas the TIR domain can act as a dominant negative. MyD88-deficient mice were shown to lack responsiveness to lipopolysaccharide (LPS), the ligand for TLR4. Several inactivating mutations in MyD88 have also been identified in humans with recurrent infections with pyogenic bacteria. These mutations, as well as some rare missense polymorphisms, are associated with reduced IRAK4 activation, leading to impaired responses through TLRs and IL-1 family members. . Phosphorylated IRAKs 1 and 2 interact with the E3 ubiquitin ligase TNF receptor–associated factor 6 (TRAF6), via their TRAF binding domains. TRAF6 ultimately recruits TAK1-binding protein 2 (TAB2) and activates TAB2-associated TGFbactivated kinase 1 (TAK1), which promotes cell survival through activation of both the canonical NF-kB (p50–p65) pathway and the mitogen-activated protein kinase (MAPK) pathway.
References
1.Deguine J, Barton GM. F1000Prime Rep. 2014;6:97.
2.Yu X, et al. Cancer Res. 2018;78(10):2457–2462.
References
1.Deguine J, Barton GM. F1000Prime Rep. 2014;6:97.
2.Yu X, et al. Cancer Res. 2018;78(10):2457–2462.
Immunology/Inflammation
Amino Acids and Derivatives(42)
Antiviral(77)
CD110(2)
Cell wall(0)
Complement System(33)
FLAP(9)
Hydroxylase(14)
Interferon Receptor(6)
IRAK(24)
IκB kinase (IKK)(41)
Lipoxygenase(53)
LTR(13)
MyD88(6)
NOS(85)
PD-1/PD-L1(38)
PGE synthase(14)
RLR(4)
ROS(61)
Scavenger Receptor(2)
SphK(3)
STING(27)
TLR(68)
MyD88
-
EM 163
产品货号 : M35255
cas no: 1206480-93-4
EM-163 是一种合成的 BB-Loop 模拟物。EM-163 可以通过靶向 MyD88 的 TIR 结构域,缓解炎症并防止中毒性休克导致的死亡。EM-163 可以用于 SEB 中毒的研究 (SEB: 葡萄球菌肠毒素 B)。 -
T6167923 B
产品货号 : M33136
cas no: 2437475-16-4
T6167923 是一种选择性的 MyD88 依赖型信号通路的抑制剂。T6167923 直接与 MyD88 的 Toll/IL1 受体 (TIR) 结构域结合,破坏 MyD88 的同二聚体形成。T6167923 抑制 NF-κB 驱动的葡萄球菌肠毒素AP (SEAP) 活性,并且改善抗炎活性,对 IFN-γ,IL-1β,IL-6 和 TNF-α 的 IC50s 分别为 2.7 ?μM,2.9 μM,2.66 μM 和 2.66 μM。 -
TJ-M2010-5
产品货号 : M28889
cas no: 1357471-57-8
TJ-M2010-5 是一种 MyD88 抑制剂,可与 TIR 结构域结合,干扰其同二聚化并抑制 MyD88 信号传导。 TJ-M2010-5可用于心肌缺血/再灌注损伤研究。 -
T5910047
产品货号 : M16793
cas no: 950003-29-9
T5910047 (T-5910047) 是 MyD88 依赖性信号通路的小分子抑制剂。 -
ST-2825
产品货号 : M16445
cas no: 894787-30-5
一种合成的肽模拟化合物,以 TIR 依赖性方式抑制 MyD88 二聚化。